doi: 10.3389/fncel.2025.1523773 20
GLP-1 receptor agonists are not recommended to be used during pregnancy, and so we can assume that the vast majority, if not all, of patients had stopped use either before or soon after conception, Nau told Healio
14 Notably, the majority of the epidemiological investigations included in this study (with the exception of two regional studies in Germany and one early study from Denmark) consistently indicated a continuous upward trend in AP incidence across Europe, with a median annual increase of 2.3%
Hunger increases, fullness becomes less reliable, and metabolic adaptation makes maintenance difficult
That may be a possibility
Dosing should follow established protocols rather than experimental high-dose approaches